CSL Behring Uses Specialty Label System to Blind Vials for Clinical Trials

There are visible differences between the candidate and the placebo in this international Phase III trial. The blinding system combines a cap system that completely covers the vial with a booklet label for multilingual product information.

The combination of Flexi-Cap and Booklet-Label blinds the vial and offers ample space for product information in several languages.
The combination of Flexi-Cap and Booklet-Label blinds the vial and offers ample space for product information in several languages.

Blinding in clinical trials must not be overlooked. Back in 2013, Wan et al noted in Blinding in Pharmacological Trials: The Devil is in the Details that inadequate blinding in pharmacological trials can lead to trial delays and increased costs,and can also potentially place the entire trial at risk.”

A specialist in plasma-derived products, CSL Behring develops and produces biopharmaceuticals for bleeding disorders, immunoglobulins and intensive-care medicine. The biotech company is conducting an international Phase III study of a new immunoglobolin and is relying on a novel label combination from Schreiner MediPharm, a Germany-based global provider of functional label solutions for the healthcare industry.


See it Live at PACK EXPO Connects Nov. 9-13: Automation Solutions for Every Budget, by MGS. Preview the Showroom Here.

Annual Outlook Report: Workforce
Hiring remains a major challenge in packaging, with 78% struggling to fill unskilled roles and 84% lacking experienced workers. As automation grows, companies must rethink hiring and training. Download the full report for key insights.
Download Now
Annual Outlook Report: Workforce
Annual Outlook Report: Automation & Robotics
What's in store for CPGs in 2025 and beyond? Packaging World editors explore the survey responses from 118 brand owners, CPG, and FMCG Packaging World readers for its new Annual Outlook Report.
Download
Annual Outlook Report: Automation & Robotics